Lartruvo (olaratumab) was the first new drug approved for soft tissue sarcoma in more than four decades, at the time offering patients with the tough-to-treat...
CAR-T therapies represent a significant clinical advance for patients with certain types of advanced lymphoma. In clinical testing, Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) induced...
Biopharma companies wanting to treat rare diseases are increasingly pressed to be invested in gene therapy.
Novartis and Roche have recognized this with their...
The RDC prosecution could serve as a warning to the drug distribution industry, potentially impacting litigation against the three largest players: McKesson, AmerisourceBergen and...
Biologics have been a business boon to contract manufacturers, Catalent included.
Large-molecule drugs are such a focus, in fact, that last year Catalent split its...
Roche's $4.8 billion takeout of gene therapy specialist Spark Therapeutics looked like a typical biopharma transaction — that is, until the Federal Trade Commission...
Biopharma companies wanting to treat rare diseases are increasingly pressed to be invested in gene therapy.
Novartis and Roche have recognized this with their...
The administration faces increasing pressure to release a concrete healthcare plan as Democratic presidential candidates are eager to keep the national conversation focused...
Novo is best known for its insulin products like Levemir (insulin detemir) and Tresiba (insulin degludec), as well as other diabetes treatments like...
